Ndrepepa Gjin, Mehilli Julinda, Schwaiger Markus, Schühlen Helmut, Nekolla Stephan, Martinoff Stefan, Schmitt Claus, Dirschinger Josef, Schömig Albert, Kastrati Adnan
Deutsches Herzzentrum, Munich, Germany.
J Nucl Med. 2004 May;45(5):725-9.
Myocardial salvage assessed by (99m)Tc-sestamibi scintigraphy is a marker of myocardial tissue reperfusion in patients with acute myocardial infarction. The prognostic value of myocardial salvage index in patients with acute myocardial infarction after reperfusion therapy has not, however, been investigated.
We analyzed 765 patients with acute myocardial infarction randomized to treatment by coronary stenting (383 patients), primary coronary angioplasty (251 patients), or thrombolysis (131 patients) in the setting of 3 randomized trials. Initial (before reperfusion therapy) and follow-up (7-14 d after reperfusion therapy) scintigraphic examinations were performed to assess the initial perfusion defect, final infarct size, and salvage index. Patients were categorized into 2 groups defined by the median salvage index (0.5): the group with salvage index < 0.5 (374 patients) and the group with salvage index >or= 0.5 (391 patients). The primary endpoint of the study was mortality at 6 mo after the index event.
Six-month mortality was 5.1% (19 deaths) in the group with salvage index < 0.5, compared with 1.0% (4 deaths) in the group with salvage index >or= 0.5 (odds ratio, 5.1; 95% confidence interval, 1.9-13.3; P = 0.001). Salvage index (median [25th, 75th percentiles] was significantly smaller in nonsurvivors than in survivors (0.19 [0.05, 0.37] vs. 0.50 [0.26, 0.80], P = 0.0004). The Cox proportional hazards model showed that myocardial salvage index (P = 0.0007), initial perfusion defect (P = 0.0007), and age (P = 0.04) were independently associated with 6-mo mortality.
Myocardial salvage achieved by reperfusion therapy predicts mortality in patients with acute myocardial infarction. Our findings support the use of salvage index as a surrogate of mortality in clinical trials designed to test the efficacy of reperfusion therapies among patients with acute myocardial infarction.
通过(99m)锝- sestamibi闪烁显像评估的心肌挽救是急性心肌梗死患者心肌组织再灌注的一个标志物。然而,再灌注治疗后急性心肌梗死患者心肌挽救指数的预后价值尚未得到研究。
我们在3项随机试验中分析了765例急性心肌梗死患者,这些患者被随机分配接受冠状动脉支架置入术(383例患者)、直接冠状动脉血管成形术(251例患者)或溶栓治疗(131例患者)。在再灌注治疗前进行初始闪烁显像检查,并在再灌注治疗后7 - 14天进行随访闪烁显像检查,以评估初始灌注缺损、最终梗死面积和挽救指数。患者根据挽救指数中位数(0.5)分为两组:挽救指数<0.5的组(374例患者)和挽救指数≥0.5的组(391例患者)。研究的主要终点是索引事件后6个月的死亡率。
挽救指数<0.5的组6个月死亡率为5.1%(19例死亡),而挽救指数≥0.5的组为1.0%(4例死亡)(比值比,5.1;95%置信区间,1.9 - 13.3;P = 0.001)。非幸存者的挽救指数(中位数[第25、75百分位数])显著低于幸存者(0.19 [0.05, 0.37]对0.50 [0.26, 0.80],P = 0.0004)。Cox比例风险模型显示,心肌挽救指数(P = 0.0007)、初始灌注缺损(P = 0.0007)和年龄(P = 0.04)与6个月死亡率独立相关。
再灌注治疗实现的心肌挽救可预测急性心肌梗死患者的死亡率。我们的研究结果支持在旨在测试急性心肌梗死患者再灌注治疗疗效的临床试验中,将挽救指数用作死亡率的替代指标。